Abstracts tagged "race/ethnicity"

Abstract Number: 0297 • ACR Convergence 2024
Characteristics of Adult-Onset Still’s Disease Skin Eruption in Individuals of Sub-Saharan Ancestry
Benoit Suzon¹, Eleonore de Fritsch¹, Arthur Felix¹, Fabienne Louis-sidney², Emmanuelle Amazan¹, Florence Moinet³, Aurore Abel¹, Illitch Coco-Viloin¹, Moustapha Dramé¹, Christophe Deligny⁴ and Pernelle Thomas¹, ¹University Hospital of Martinique, Fort-de-France, Martinique, ²University Hospital Martinique, Fort De France, Martinique, ³University Hospital of Martinique, Fort de France, France, ⁴University Hospital of Martinique - National reference center for autoimmune disease, Internal Medicine, Fort-de-France, Martinique
Background/Purpose: There is no data about adult-onset Still's disease (AOSD) skin eruption in individuals of sub-Saharan ancestry, from basic description to potential clinical implications.Methods: We conducted…
Abstract Number: 1747 • ACR Convergence 2024
Native Americans Experience Profound Premature Mortality from Rheumatoid Arthritis
Parmita Das¹, Snehin Rajkumar², Eric Yen³ and Ram Singh⁴, ¹University of California Los Angeles, Saint Johns, ²UCLA David Geffen School of Medicine, Irvine, CA, ³UCLA, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic debilitating disease affecting up to 1% of the US population and has variable outcomes by race/ethnicity. We analyzed…
Abstract Number: 0353 • ACR Convergence 2024
Identifying Solutions to Address Racial and Ethnic Health Disparities in Lupus: A Consensus-Based Approach
Joy Buie¹, Michael Fisher¹, Hannah Tlydsley², Kristen Backor² and Karen Costenbader³, ¹Lupus Foundation of America, Washington, DC, ²Charles River Associates, San Francisco, CA, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: Health disparities among racial and ethnic minoritized individuals living with lupus remain a critical public health concern. Challenges related to healthcare affordability, accessibility, and…
Abstract Number: 1803 • ACR Convergence 2024
Genetics of eGFR Variability as a Proxy for Lupus Nephritis in Patients with Systemic Lupus Erythematosus
Magdalena Riedl Khursigara¹, Nicholas Gold², Thai-Son Tang³, JingJing Cao⁴, Daniela Dominguez⁴, Marisa Klein-Gitelman⁵, Dafna Gladman⁶, Daniel Goldman⁷, Elizabeth Harvey⁴, Mariko Ishimori⁸, Caroline Jefferies⁹, Diane Kamen¹⁰, Sylvia Kamphuis¹¹, Andrea Knight¹², Chia-Chi Lee¹³, Deborah Levy², Damien Noone⁴, Karen Onel¹⁴, Christine Peschken¹⁵, Michelle Petri⁷, Janet Pope¹⁶, Eleanor Pullenayegum⁴, Earl Silverman¹⁷, Zahi Touma¹⁸, Murray Urowitz¹⁹, Daniel Wallace²⁰, Joan Wither²¹ and Linda Hiraki², and Systemic Lupus Erythematosus Collaborative Clinics (SLICC), ¹University of Toronto, Cambridge, MA, ²The Hospital for Sick Children, Toronto, ON, Canada, ³University of Toronto, Mississauga, ON, Canada, ⁴The Hospital for Sick Children, Toronto, Canada, ⁵Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Johns Hopkins University School of Medicine, Timonium, MD, ⁸Cedars-Sinai Health System, Los Angeles, CA, ⁹Cedars-Sinai Medical Center, Beverly Hills, CA, ¹⁰Medical University of South Carolina, Charleston, SC, ¹¹Erasmus University Medical Center, Rotterdam, Netherlands, ¹²Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ¹³Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁴HSS, New York, NY, ¹⁵University of Manitoba, Winnipeg, MB, Canada, ¹⁶University of Western Ontario, London, ON, Canada, ¹⁷Silverman, Toronto, ON, Canada, ¹⁸University of Toronto, Toronto, ON, Canada, ¹⁹Self employed, Toronto, ON, Canada, ²⁰Cedars Sinai Medical Center, Studio City, CA, ²¹University Health Network, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) is one of the most common and severe manifestations of systemic lupus erythematosus (SLE). We performed genome wide association studies (GWAS)…
Abstract Number: 0177 • ACR Convergence 2023
Cost-Related Medication Non-Adherence Among US Adults with Chronic Arthritis: Trends, Comparisons, and Disparities
Ashkan Ara¹, Matthew Chenoweth¹, Christopher Scannell² and John FitzGerald¹, ¹University of California Los Angeles, Los Angeles, CA, ²UCLA / West Los Angeles VA Medical Center, Los Angeles, CA
Background/Purpose: Cost-related medication non-adherence (CRN), a measure of drug affordability, refers to a patient's inability to adhere to a prescribed medication regimen due to high…
Abstract Number: 1030 • ACR Convergence 2023
Patterns in the Prescription, the Denials of Coverage, and the Delays in Dispensation of Janus Kinase Inhibitors
Thomas Riley¹, Igor Dombrovsky², Michael George³ and Joshua Baker³, ¹Hopsital of the University of Pennsylvania, Springfield, PA, ²Pennsylvania Hospital, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Janus kinase inhibitors (JAKi) have therapeutic benefits in autoimmune conditions. Access to these medications is controlled by insurance carriers through requirements for prior authorizations…
Abstract Number: 2459 • ACR Convergence 2023
Reporting of Race and Ethnicity in Lupus Publications in High-impact Rheumatology Journals
Idil Eroglu, Hailey Baker, Mario Felix and Lisa Suter, Yale School of Medicine, New Haven, CT
Background/Purpose: Reporting of race and ethnicity as social constructs is critical to highlight equity and diversity of study participants, with the knowledge that socio-economic factors…
Abstract Number: 0178 • ACR Convergence 2023
Traditional and Lupus-Specific Risk Factors for Cardiovascular Events Among Patients with Systemic Lupus Erythematosus
Saloni Patolia, Dulaney Wilson, Jim Oates and Diane L. Kamen, Medical University of South Carolina, Charleston, SC
Background/Purpose: Even among young women with systemic lupus erythematosus (SLE), accelerated atherosclerosis and coronary artery disease are common complications. Traditional risk scoring methods underestimate cardiovascular…
Abstract Number: 1032 • ACR Convergence 2023
“Not of Your Ethnicity”: A Qualitative Study Exploring Diverse Patient Experiences in Axial Spondyloarthritis (axSpA)
Bryanna Mantilla¹, K Wysham², Jean liew³ and Grant Hughes¹, ¹University of Washington, Seattle, WA, ²VA Puget Sound/University of Washington, Seattle, WA, ³Boston University, Boston, MA
Background/Purpose: Axial spondyloarthritis (axSpA) can result in significant morbidity. Existing studies suggest functional impairment and inflammation may be worse in Black and Latine patients. However,…
Abstract Number: 2523 • ACR Convergence 2023
Region, Race, and Hospital Factors Impact Length of Stay and Hospital Charges Post-primary Total Knee Arthroplasty
Kranti Rumalla¹, Sumanth Chandrupatla² and Jasvinder Singh², ¹Northwestern School of Medicine, Chicago, IL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Osteoarthritis (OA) affects nearly 33 million adults in the US and total knee arthroplasty (TKA) is an effective treatment. Outcomes can vary by regional…
Abstract Number: 0190 • ACR Convergence 2023
Racial Disparities in Self-reported Extent and Reasons for Nonadherence in SLE
Kai Sun¹, Londyn Robinson², Amanda Eudy³, Jennifer Rogers¹, Rebecca Sadun¹, Lisa Criscione-Schreiber⁴, Jayanth Doss¹ and Megan Clowse⁵, ¹Duke University, Durham, NC, ²University of Minnesota Medical School, Minneapolis, MN, ³Duke University, Raleigh, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵Duke University, Chapel Hill, NC
Background/Purpose: Medication nonadherence is common in SLE and disproportionately affects Black patients. Nonadherence leads to increased hospitalizations, morbidity, and mortality and is a modifiable factor…
Abstract Number: 1163 • ACR Convergence 2023
Anti-melanoma Differentiation Associated Gene 5 (Anti-MDA5) Antibody Dermatomyositis: Clinical Features and Outcome in a Racially Diverse Patient Cohort
Sai Koyoda¹, Dawn Wahezi², Xianhong Xie³, Anand Kumthekar⁴, Clement Tagoe³ and Bibi Ayesha⁵, ¹Essen Medical Center, Rahway, NJ, ²Children's Hospital at Montefiore, New Rochelle, NY, ³Albert Einstein College of Medicine, Bronx, NY, ⁴Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ⁵Montefiore Medical Center, Bronx, NY
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody dermatomyositis typically expresses rapidly progressing interstitial lung disease (RP-ILD) and ulcerative skin lesions, with or without muscle involvement.…
Abstract Number: 0191 • ACR Convergence 2023
Reproductive Health Discussions Between Rheumatology Providers and Systemic Lupus Erythematosus Patients: A Survey of English and Spanish-Speaking Patients
Meredith Xepoleas¹, Martha Delgado², Jack Rodman³, Julia Simard⁴, Sandy Lee⁵ and Leanna Wise⁶, ¹Keck School of Medicine of University of Southern California, Los Angeles, CA, ²LAC+USC/Keck School of Medicine, Los Angeles, CA, ³University of Southern California, Los Angeles, CA, ⁴Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ⁵University of Southern California, Walnut, CA, ⁶LAC+USC/Keck Medicine of USC, Pasadena, CA
Background/Purpose: Systemic lupus erythematosus (SLE) primarily affects women of childbearing age, with a higher burden in non-Caucasian populations. Due to the increased risk of adverse…
Abstract Number: 1212 • ACR Convergence 2023
Racial Disparities in Comorbidities and Perception of Physical Health in Systemic Lupus Erythematosus
OKEOGHENE AKPOIGBE¹, YONG EUN², COMFORT ANIM-KORANTENG² and AMANDA SAMMUT², ¹NYCHH- HARLEM, Bronx, NY, ²NYCHH- HARLEM, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multisystemic immune-mediated disease with often nonspecific symptoms, associated with recurrent flares that can be life threatening. Prevalence…
Abstract Number: 0240 • ACR Convergence 2023
Gout: A Gateway to Chronic Opioid Use?
Lindsay Helget¹, Bryant England¹, Punyasha Roul¹, Harlan Sayles¹, Tuhina Neogi², James O'Dell¹ and Ted R Mikuls³, ¹University of Nebraska Medical Center, Omaha, NE, ²Boston University School of Medicine, Boston, MA, ³Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Painful gout flares often lead to healthcare visits which, based on prior reports, results in the use of opioid therapy for flare management, despite…

« Previous Page
1
…
4
5
6
7
8
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].